Physician profile
Troy D Kramer
NPI 1831108620
$1,668.84
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $339 · 2021: $163 · 2022: $200 · 2023: $74.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $740.63 | 2019-2023 | Uptravi |
| Insmed, INC. | $263.79 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $213.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $65.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.26 | 2019-2020 | |
| Pfizer INC. | $50.50 | 2019-2020 | |
| Grifols USA, LLC | $50.22 | 2019 | |
| Ekos Corporation | $36.55 | 2019 | |
| Mallinckrodt Enterprises LLC | $26.49 | 2019 | |
| Allergan, INC. | $24.15 | 2019 | |
| Circassia INC. | $19.97 | 2020 | |
| Portola Pharmaceuticals, LLC | $19.34 | 2019 | |
| Csl Behring | $19.21 | 2020 | |
| Gilead Sciences, INC. | $17.04 | 2019 | |
| Philips North America LLC | $15.67 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.78 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.